Our laboratory is focused on understanding the underlying biology of the renal cell carcinomas. This set of diseases affects over 50,000 new patients annually in the US. Recent molecular discoveries based on understanding the hypoxia response pathway have led to the development of multiple new lines of treatment for this cancer, and new targeted therapies and immunotherapies are demonstrating effectiveness as well. Our goal is to identify strategies to improve the treatment of cancers based on biomarker approaches to defining drivers of the cancer phenotype, or developing better ways to detect these cancers earlier. Therefore, our research takes a broad approach using genetic techniques to study tumor initiating events and events that promote the development of invasive or metastatic features using in vitro, animal, and human systems. This translational research, all geared toward enhancing our understanding of the genetics and molecular biology of kidney derived cancers, is folded into a clinical research program at the Vanderbilt-Ingram Cancer Center.